Peptides DB
Research-centric peptide and protocol reference hub
Study 17 of 17HMG (Human Menopausal Gonadotropin) literaturebiorxiv-preprint · Observational2021

Comparison between the efficacy of short and long GnRH-a protocols as a clinical outcome for viable pregnancies in women undergoing IVF/ICSI Cycles.

The long acting GnRH-a protocol showed a higher clinical pregnancy rate of 33.12% compared to 28.23% for the short acting protocol, indicating a potential preference for the long acting approach in IVF/ICSI cycles.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the hmg (human menopausal gonadotropin) corpus
0
Preclinical
13
Observational · this one
0
Open-label
3
Randomised
1
Reviews

Summary and findings

This study compared the efficacy of short and long acting GnRH-a protocols on pregnancy outcomes in women undergoing IVF/ICSI cycles. A total of 540 cycles were analyzed, with the long acting protocol showing higher clinical pregnancy rates and other metrics compared to the short acting protocol. No therapeutic claims are made.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Clinical pregnancy rates: LAP 33.12% vs SAP 28.23%, p=0.001.2021

Abstract

The authors’ words, as biorxiv-preprint supplied them

This retrospective case control study was executed to compare the efficacy of short and long acting Gonadotropin releasing hormone agonist (GnRH-a) on pregnancy outcome. A total of 540 cycles with a history of male factor were identified from 2013 to 2016. The patients were separated into two groups: long acting protocol (LAP) group consisting of 310 cycles which were induced by a combination of GnRH-a incorporated with Follicular stimulating hormone (FSH) and Human menopausal gonadotropin (hMG), while short acting protocol (SAP) group or flare up regimen comprises of 230 cycles introduced by a combination of GnRH-a along with FSH and hMG. Patients are divided into subsequent age groups ≤ 30, 31–35, 36–40 and > 40 years. In comparison with the SAP group, the duration of ovarian stimulation, calculated dose of GnRH-a, number of retrieved mature oocytes, good quality embryos for implantation and persistent pregnancies were all significantly found to be high ( p  < 0.05) in the LAP group as compared to the SAP group. The clinical pregnancy rates were comparatively high in the LAP group (33.12%; P  = 0.001) than in the SAP group (28.23%). The findings of our study revealed that irrespective of patient’s age, the long acting protocol was more reliable and fertile with reference to number of mature oocytes retrieved, time period for stimulation, total dose of GnRH-a during controlled ovarian hyperstimulation, high quality embryos, fertilization and cleavage rate as well as pregnancy outcome.

Elsewhere in the HMG (Human Menopausal Gonadotropin) corpus

BRecombinant Follicular Stimulating Hormone Plus Recombinant Luteinizing Hormone Versus Human Menopausal Gonadotropins- Does the Source of LH Bioactivity Affect Ovarian Stimulation Outcome?biorxiv-preprint · 2021 · Mean number of mature oocytes retrieved: 10 ± 5.8 in rFSH+rLH vs 8.3 ± 4.6 in HP-hMG, p=0.01.HumanBUsing Letrozole Cotreatment With Progestin-Primed Ovarian Stimulation In Women With Polycystic Ovary Syndrome Treated For IVFbiorxiv-preprint · 2021 · 42.22% implantation rate in letrozole group vs. 34.69% in control group, p<0.05HumanBEvaluation of assisted reproductive technology treatment outcomes based on stimulation dosages and anti-Mullerian hormone levelsbiorxiv-preprint · 2022 · Not reported in abstract.HumanBHighly purified-hMG versus rFSH in ovarian hyperstimulation in women undergoing elective fertility preservationbiorxiv-preprint · 2023 · Peak estradiol level was significantly lower in the rFSH group (2547.18±1648.21 pg/mL) than in the hp-hMG group (3468.02±2497.69 pg/mL, P<0.001).HumanBA FSH-secreting pituitary adenoma discovered after ovarian hyperstimulation syndrome: a case report, illustrating pitfalls in the interpretation of serum FSH levelsbiorxiv-preprint · 2024 · Estradiol elevated at 737 pg/ml.HumanCErzhi Tiangui formula ameliorates ovarian aging by enhancing antioxidant defense via Nrf2/HO-1 signaling.europepmc · 2026 · Not reported in abstract.Animal